Skip to main content
. Author manuscript; available in PMC: 2019 Dec 16.
Published in final edited form as: Sci Immunol. 2019 May 17;4(35):eaax0644. doi: 10.1126/sciimmunol.aax0644

Figure 1. CRISPR/Cas9 mediated replacement of an endogenous antibody with an engineered monoclonal antibody (emAb).

Figure 1.

(A) Diagram showing insertion of an emAb cassette containing a heavy chain promoter, full light chain, linker, and partial heavy chain into the intronic region between the terminal J segment and the Eμ enhancer, upstream of the endogenous heavy chain constant region exons. (B) Schematic showing normal transmembrane and secreted antibody versus transmembrane and secreted emAb with the endogenous heavy chain constant regions shown in grey.